JP7732999B2 - アルファ１－アンチトリプシンのモジュレーター - Google Patents

アルファ１－アンチトリプシンのモジュレーター

Info

Publication number
JP7732999B2
JP7732999B2 JP2022559582A JP2022559582A JP7732999B2 JP 7732999 B2 JP7732999 B2 JP 7732999B2 JP 2022559582 A JP2022559582 A JP 2022559582A JP 2022559582 A JP2022559582 A JP 2022559582A JP 7732999 B2 JP7732999 B2 JP 7732999B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
tautomer
mmol
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022559582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520396A5 (https=
JP2023520396A (ja
Inventor
マイケル フィリップ クラーク，
サイモン ジルー，
フィリップ ノエル コリアー，
チン タン，
ネイサン ディー． ワール，
サラティー ケサバン，
ピーター ジョーンズ，
マイケル アーロン ブロドニー，
ウェンシン グ，
ダイアン マリー バウチャー，
レブ ティー．ディー． ファニング，
エイミー ビー． ホール，
デニス ジェイムズ ハーレー，
マック アーサー ジュニア ジョンソン，
ジョン パトリック マクスウェル，
レベッカ ジェーン スウェット，
ティモシー ルイス タプレイ，
スティーブン エー． トムソン，
ヴェロニク ダマグネス，
ケヴィン マイケル コットレル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2023520396A publication Critical patent/JP2023520396A/ja
Publication of JP2023520396A5 publication Critical patent/JP2023520396A5/ja
Application granted granted Critical
Publication of JP7732999B2 publication Critical patent/JP7732999B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2022559582A 2020-04-03 2021-04-02 アルファ１－アンチトリプシンのモジュレーター Active JP7732999B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063004702P 2020-04-03 2020-04-03
US63/004,702 2020-04-03
PCT/US2021/025601 WO2021203014A1 (en) 2020-04-03 2021-04-02 Pyrano[4,3-b]l ndole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)

Publications (3)

Publication Number Publication Date
JP2023520396A JP2023520396A (ja) 2023-05-17
JP2023520396A5 JP2023520396A5 (https=) 2024-04-10
JP7732999B2 true JP7732999B2 (ja) 2025-09-02

Family

ID=75674975

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559582A Active JP7732999B2 (ja) 2020-04-03 2021-04-02 アルファ１－アンチトリプシンのモジュレーター

Country Status (7)

Country Link
US (1) US12502376B2 (https=)
EP (1) EP4126881A1 (https=)
JP (1) JP7732999B2 (https=)
CN (1) CN115768772A (https=)
AU (1) AU2021248641A1 (https=)
CA (1) CA3178470A1 (https=)
WO (1) WO2021203014A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3114672A1 (en) 2018-10-05 2020-04-23 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
JP7732999B2 (ja) 2020-04-03 2025-09-02 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ１－アンチトリプシンのモジュレーター
WO2022104353A1 (en) 2020-11-12 2022-05-19 Vertex Pharmaceuticals Incorporated Methods of monitoring alpha-1 antitrypsin (aat) deficiency by measuring polymerised aat
CN116812917B (zh) * 2022-03-21 2026-04-07 中国科学院化学研究所 一种水溶性富勒烯材料及其在防治肝损伤/肝衰竭中的应用
WO2025090827A1 (en) 2023-10-27 2025-05-01 Sub21, Inc. A1at modulators

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533031A (ja) 2002-05-21 2005-11-04 ワイス Ｃ型肝炎に対するピラノインドール誘導体のｒ−鏡像異性体類
JP2013532695A (ja) 2010-08-04 2013-08-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ６’−フルオロ−（Ｎ−メチル−又はＮ，Ｎ−ジメチル−）−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンを含む医薬剤形
WO2019243841A1 (en) 2018-06-22 2019-12-26 Ucl Business Ltd Novel compounds
JP2023520400A (ja) 2020-04-03 2023-05-17 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ－１－アンチトリプシン欠損症（ａａｔｄ）を治療するためのアルファ－１－アンチトリプシンモジュレーターとしてのインドール誘導体

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2612503A (en) 1949-04-19 1952-09-30 Smith Kline French Lab Basic ether-substituted isoquinolines
US2538341A (en) 1949-09-20 1951-01-16 Smith Kline French Lab Method for producing 1-hydroxyisoquinolines
US3404157A (en) 1965-02-24 1968-10-01 American Cyanamid Co Substituted pyrroloindazole compounds
US4198415A (en) 1979-01-22 1980-04-15 Eli Lilly And Company Prolactin inhibiting octahydro pyrazolo[3,4-g]quinolines
US4647667A (en) 1982-11-03 1987-03-03 Eli Lilly And Company Octa- and deca-hydroquinoline intermediates
US4778894A (en) 1983-09-26 1988-10-18 Eli Lilly And Company 6 oxo-decahydroquinolines
US5358949A (en) 1986-03-05 1994-10-25 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
DK158590D0 (da) 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
JPH11501004A (ja) 1995-02-01 1999-01-26 ユニヴァーシティー・カレッジ・カーディフ・コンサルタンツ・リミテッド 三環系誘導体及びそれらの抗ガン剤としての使用
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
JP2000072751A (ja) 1998-08-26 2000-03-07 Tanabe Seiyaku Co Ltd イソキノリノン誘導体
JP2000281654A (ja) 1999-03-26 2000-10-10 Tanabe Seiyaku Co Ltd イソキノリン誘導体
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
FR2802532A1 (fr) 1999-12-17 2001-06-22 Sanofi Synthelabo Derives de 2-phenyl-quinoleine, leur preparation et leur application en therapeutique
DK1242382T3 (da) 1999-12-29 2007-05-07 Wyeth Corp Tricycliske proteinkinaseinhibitorer
US6638929B2 (en) 1999-12-29 2003-10-28 Wyeth Tricyclic protein kinase inhibitors
EP1305308B1 (en) 2000-07-26 2006-12-20 Smithkline Beecham Plc Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
AU2002211901A1 (en) 2000-10-10 2002-04-22 Smithkline Beecham Corporation Substituted indoles, pharmaceutical compositions containing such indoles and their use as PPAR-gamma binding agents
US6906192B2 (en) 2000-11-07 2005-06-14 Bristol Myers Squibb Company Processes for the preparation of acid derivatives useful as serine protease inhibitors
US20030212085A1 (en) 2001-04-17 2003-11-13 Mccall Robert B. Treatment of fibromyalgia and chronic fatigue syndrome
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
US6706423B2 (en) 2001-12-27 2004-03-16 Lightronik Technology Inc. Organic EL device
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2004108120A1 (en) 2003-06-11 2004-12-16 Pfizer Products Inc. Use of growth hormone secretagogues for treatment of fibromyalgia
BRPI0412820A (pt) 2003-07-25 2006-09-26 Pfizer compostos de aminopirazol e utilização como inibidores de chk1
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
US7723352B2 (en) 2003-09-23 2010-05-25 Merck Sharp & Dohme Isoquinolinone potassium channel inhibitors
WO2006019831A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US8097644B2 (en) 2006-03-28 2012-01-17 Allergan, Inc. Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist
BRPI0710527B8 (pt) 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
DK2013619T3 (en) 2006-04-10 2017-12-04 Wisconsin Alumni Res Found METHODS FOR USING HUMAN EMBYO STEM CELLS FOR EVALUATION OF THE PHARMACEUTICAL SUBSTANCE AND OTHER CHEMICALS
TW200813054A (en) 2006-06-02 2008-03-16 Elan Pharm Inc Fused, tricyclic sulfonamide inhibitors of gamma secretase
SG176477A1 (en) 2006-08-07 2011-12-29 Ironwood Pharmaceuticals Inc Indole compounds
WO2008143633A2 (en) 2007-01-10 2008-11-27 University Of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
US20100016285A1 (en) 2007-01-24 2010-01-21 Mochida Pharmaceutical Co., Ltd. Heterocyclidene-n-(aryl) acetamide derivative
JP5107589B2 (ja) 2007-02-13 2012-12-26 旭化成株式会社 インドール誘導体
RU2337915C1 (ru) 2007-03-14 2008-11-10 Общество с ограниченной ответственностью "Инжиниринговая компания "ИНКОМП-НЕФТЬ" Комплексонат нитрилотри(метиленфосфонато)-2-фенил-3-этил-8-оксихинолин натриевая соль в качестве ингибитора солеотложений
GB0722055D0 (en) 2007-11-09 2007-12-19 Argenta Discovery Ltd Compounds
DE102008022521A1 (de) 2008-05-07 2009-11-12 Bayer Schering Pharma Aktiengesellschaft 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung
JP4856667B2 (ja) 2008-03-27 2012-01-18 ジヤトコ株式会社 自動変速機における回転軸の支持構造
HUE025471T2 (hu) 2008-04-16 2016-03-29 Karobio Ab Új ösztrogén receptor ligandumok
WO2009158587A1 (en) 2008-06-26 2009-12-30 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
WO2011056222A1 (en) 2009-11-05 2011-05-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein aggregation
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
EP2566869B1 (en) 2010-05-07 2016-03-02 Gilead Connecticut, Inc. Pyridone and aza-pyridone compounds and methods of use
KR101753447B1 (ko) 2010-09-24 2017-07-03 그리폴스 테라퓨틱스 인코포레이티드 면역크로마토그래피 장치, 방법 및 키트
US20130167932A1 (en) 2010-11-08 2013-07-04 Nec Corporation Indole compound, and photoelectric conversion dye using same, semiconductor electrode, photoelectric conversion element, and photoelectrochemical cell
JPWO2012111610A1 (ja) 2011-02-14 2014-07-07 日本電気株式会社 チアゾール系化合物及びその用途
WO2012178102A2 (en) 2011-06-24 2012-12-27 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
CN103239451A (zh) 2012-02-10 2013-08-14 上海医学生命科学研究中心有限公司 吡咯并喹啉醌在治疗和/或预防肝纤维化中的应用
US20140135359A1 (en) 2012-11-12 2014-05-15 Louis C. Martineau Methods of designing, preparing, and using novel protonophores
AP2016008970A0 (en) 2013-07-10 2016-01-31 Bayer Pharma AG Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
US9572794B2 (en) 2014-08-06 2017-02-21 Vanderbilt University Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists
WO2016154051A1 (en) 2015-03-20 2016-09-29 University Of Florida Research Foundation, Inc. Combination therapy for treating infections diseases
WO2017035418A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for treatment of immune and inflammatory disorders
JP7046814B2 (ja) 2015-12-30 2022-04-04 ジェネンテック， インコーポレイテッド タンパク質製剤のためのトリプトファン誘導体の使用
ES2910787T3 (es) 2016-05-12 2022-05-13 Univ Michigan Regents Inhibidores de ASH1L y métodos de tratamiento con los mismos
CA3024522C (en) 2016-05-31 2024-06-25 Polyphor Ag Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof
CA3047336A1 (en) 2017-01-23 2018-07-26 Jecure Therapeutics, Inc. Chemical compounds as inhibitors of interleukin-1 activity
UY37581A (es) 2017-02-02 2018-08-31 Gilead Sciences Inc Compuestos para el tratamiento de la infección por virus de la hepatitis b
EP3630109A4 (en) 2017-05-26 2021-03-17 Rutgers, the State University of New Jersey BACTERIAL EFFLUX PUMP INHIBITORS
US20200247815A1 (en) 2017-10-19 2020-08-06 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Pyrazolyl-containing tricyclic derivative, preparation method therefor and use thereof
PE20201170A1 (es) 2017-11-01 2020-10-28 Bristol Myers Squibb Co Compuestos biciclicos en puente como moduladores del receptor farnesoide x
CN107698505A (zh) 2017-11-20 2018-02-16 孙婷婷 一种诺得司他的制备方法
SMT202200396T1 (it) 2017-12-13 2022-11-18 Lupin Ltd Composti eterociclici biciclici sostituiti come inibitori di prmt5
CN111971278B (zh) 2018-01-31 2023-08-11 默克专利有限公司 用作irak抑制剂的喹啉化合物及其用途
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3620164A1 (en) 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
CA3114672A1 (en) 2018-10-05 2020-04-23 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
CN110776459B (zh) 2019-03-19 2023-01-24 江苏知原药业股份有限公司 7-羟基-2-喹诺酮-二硫代氨基甲酸酯类胆碱酯酶抑制剂
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
TW202116303A (zh) 2019-10-02 2021-05-01 美商維泰克斯製藥公司 α—１抗胰蛋白酶缺乏症之治療方法
BR112022014861A2 (pt) 2020-01-30 2022-09-20 Vertex Pharma Métodos de tratamento para deficiência de alfa-1 antittripsina
CN115697969A (zh) 2020-04-03 2023-02-03 弗特克斯药品有限公司 作为用于治疗α-1抗胰蛋白酶缺乏症(AATD)的α-1抗胰蛋白酶调节剂的7-或8-羟基-异喹啉和7-或8-羟基-喹啉衍生物
WO2021203025A1 (en) 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated 1 h-pyrazolo[4,3-g]isoquinoline and 1 h-pyrazolo[4,3-g]quinoline derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
JP7732999B2 (ja) 2020-04-03 2025-09-02 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ１－アンチトリプシンのモジュレーター
CN115776984A (zh) 2020-04-03 2023-03-10 弗特克斯药品有限公司 作为用于治疗α-1抗胰蛋白酶缺乏症(AATD)的α-1-抗胰蛋白酶调节剂的吡咯并[2,3-f]吲唑和2,4,5,10-四氮杂三环[7.3.0.03,7]十二碳-1,3(7),5,8,11-五烯衍生物
AU2021246104A1 (en) 2020-04-03 2022-10-20 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
WO2022026372A2 (en) 2020-07-27 2022-02-03 Vertex Pharmaceuticals Incorporated Processes for preparing modulators of alpha-1 antitrypsin
WO2022104353A1 (en) 2020-11-12 2022-05-19 Vertex Pharmaceuticals Incorporated Methods of monitoring alpha-1 antitrypsin (aat) deficiency by measuring polymerised aat
AU2021381509A1 (en) 2020-11-17 2023-06-22 Vertex Pharmaceuticals Incorporated Solid forms of 4-(5-(4-fluorophenyl)-6-tetrahydro-2h-pyran-4-yl)- 1,5-dihydropyrrolo[2,3-f]indazol-7-yl)benzoic acid
PE20251573A1 (es) 2022-09-09 2025-06-12 Vertex Pharma Moduladores de la alfa-1 antitripsina

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533031A (ja) 2002-05-21 2005-11-04 ワイス Ｃ型肝炎に対するピラノインドール誘導体のｒ−鏡像異性体類
JP2013532695A (ja) 2010-08-04 2013-08-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ６’−フルオロ−（Ｎ−メチル−又はＮ，Ｎ−ジメチル−）−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンを含む医薬剤形
WO2019243841A1 (en) 2018-06-22 2019-12-26 Ucl Business Ltd Novel compounds
JP2023520400A (ja) 2020-04-03 2023-05-17 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ－１－アンチトリプシン欠損症（ａａｔｄ）を治療するためのアルファ－１－アンチトリプシンモジュレーターとしてのインドール誘導体

Also Published As

Publication number Publication date
WO2021203014A1 (en) 2021-10-07
JP2023520396A (ja) 2023-05-17
CN115768772A (zh) 2023-03-07
EP4126881A1 (en) 2023-02-08
AU2021248641A1 (en) 2022-10-27
US12502376B2 (en) 2025-12-23
US20230157999A1 (en) 2023-05-25
CA3178470A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
JP7732999B2 (ja) アルファ１－アンチトリプシンのモジュレーター
CN112424185B (zh) 含苯环的化合物、其制备方法及应用
CN113474338A (zh) 吡嗪类衍生物及其在抑制shp2中的应用
JP2022515369A (ja) Ａｐｏｌ１の阻害剤及びその使用方法
JP7396369B2 (ja) アミド系化合物の調製方法及びその医学分野での使用
CN115715292B (zh) α-1-抗胰蛋白酶调节剂
JP2023520398A (ja) アルファ１－アンチトリプシンのモジュレーター
JP7733670B2 (ja) アルファ１－アンチトリプシンのモジュレーター
WO2018181345A1 (ja) 複素環化合物
JP2022511213A (ja) 細胞壊死阻害剤、その調製方法およびその使用
CN115867346B (zh) 激酶抑制剂
JP7791102B2 (ja) アルファ１－アンチトリプシンのモジュレーター
WO2021043116A1 (zh) 联苯类化合物及其制备方法和医药用途
CN105001213A (zh) C-芳基糖苷衍生物、其药物组合物、制备方法及应用
JP2023520400A (ja) アルファ－１－アンチトリプシン欠損症（ａａｔｄ）を治療するためのアルファ－１－アンチトリプシンモジュレーターとしてのインドール誘導体
JP2025532510A (ja) アルファ－１アンチトリプシンの調節剤
CN113544129A (zh) 三环类化合物制备方法及其在医药领域的应用
WO2019218956A1 (zh) 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的化合物
WO2018161871A1 (zh) 作为p53-MDM2抑制剂的咪唑并吡咯酮化合物
CN105017236A (zh) C-芳基糖苷衍生物、其药物组合物、制备方法及应用
CN117015528A (zh) 作为激酶抑制剂的吲哚衍生物
CN115916749B (en) Alpha-1 antitrypsin modulators
TW202608883A (zh) Nlrp3抑制劑及其製備方法和用途
WO2026002142A1 (zh) 一种蛋白酪氨酸激酶抑制剂的半琥珀酸盐晶型
WO2021208850A1 (zh) 硝基咪唑类衍生物及其制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240328

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250519

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250821

R150 Certificate of patent or registration of utility model

Ref document number: 7732999

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150